What is Carrick Therapeutics?
Founded in 2016, Carrick Therapeutics operates at the intersection of advanced molecular biology and clinical oncology. The company distinguishes itself by moving beyond single-compound development, instead focusing on the underlying pathways that drive cancer resistance. By integrating cutting-edge diagnostic technologies with a proprietary therapeutic portfolio, Carrick aims to identify specific patient populations that will derive the most significant benefit from its interventions. This data-driven, patient-centric model positions the firm as a critical player in the evolving landscape of precision oncology, where the focus is shifting toward highly targeted, mechanism-specific treatments.
How much funding has Carrick Therapeutics raised?
Carrick Therapeutics has raised a total of $149.5M across 3 funding rounds:
Series A
$95M
Series C
$19.5M
Other Financing Round
$35M
Series A (2016): $95M with participation from ARCH Venture Partners, Evotec AG, Woodford Investment Management, Google Ventures, Lightstone Ventures, Cambridge Innovation Capital, and Cambridge Enterprise
Series C (2022): $19.5M led by Lightspeed Venture Partners, Evotec, GV, Rosetta Capital, and Arch Venture Fund
Other Financing Round (2022): $35M supported by Pfizer
Key Investors in Carrick Therapeutics
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations.
Evotec AG
Evotec is a global platform company leveraging a data-driven multimodality approach for both proprietary and partnered research to discover and develop first-in-class pharmaceutical products.
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address significant health challenges.
What's next for Carrick Therapeutics?
With the successful closure of its latest financing, Carrick Therapeutics is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic nature of the recent capital injection suggests a focus on scaling operations and potentially advancing lead candidates through critical regulatory milestones. Moving forward, the company is expected to deepen its collaborative efforts with global biopharmaceutical partners to validate its platform's efficacy. As the firm matures, the emphasis will likely remain on optimizing its pipeline to address the most challenging forms of cancer, thereby enhancing its long-term value proposition in the competitive biotechnology market.
See full Carrick Therapeutics company page
